Keywords
How to Cite
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most pressing issues in modern hepatology, endocrinology, and metabolic medicine. Its development is closely associated with insulin resistance, visceral obesity, dyslipidemia, chronic low-grade inflammation, oxidative stress, and fibrotic processes. In recent years, international hepatology literature has increasingly referred to this condition as metabolic dysfunction-associated steatotic liver disease (MASLD). According to the 2024 clinical guidelines of the European associations for liver, diabetes, and obesity research, MASLD is characterized by hepatic steatosis accompanied by at least one cardiometabolic risk factor. This study focuses on the hormonal and genetic features of sex hormone metabolism in women of reproductive age with non-alcoholic fatty liver disease, highlighting the role of endocrine and genetic factors in the pathogenesis and progression of the disease.
References
1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. – 2024. – Vol. 81, Issue 3. – P. 492–542. DOI: 10.1016/j.jhep.2024.04.031. Elektron manba: ScienceDirect / Journal of Hepatology.
2. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., Kleiner D.E., Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. – 2023. – Vol. 77, №5. – P. 1797–1835. DOI: 10.1097/HEP. 00323. PMID: 36727674. Elektron manba: PubMed.
3. Weiskirchen R., Lonardo A. Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease // International Journal of Molecular Sciences. – 2025. – Vol. 26. – Article 9594. Elektron manba: PubMed Central.
4. Fernández-Alonso A.M., Chedraui P., Pérez-López F.R. Nonalcoholic fatty liver disease risk in polycystic ovary syndrome patients // Gynecological Endocrinology. – 2024. – Vol. 40, №1. – Article 2359031. DOI: 10.1080/09513590.2024.2359031. PMID: 38813954. Elektron manba: Taylor & Francis / PubMed.
5. Di Stasi V., Maseroli E., Rastrelli G., Scavello I., Cipriani S., Todisco T., Marchiani S., Sorbi F. va boshq. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction // Frontiers in Endocrinology. – 2021. – Vol. 12. – Article 641446. DOI: 10.3389/fendo.2021.641446. PMID: 33854482. Elektron manba: Frontiers / PubMed.
6. Xing C., Zhao H., Zhang J., He B. The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis // Frontiers in Physiology. – 2022. – Vol. 13. – Article 741285. DOI: 10.3389/fphys.2022.741285. PMID: 35615684. Elektron manba: Frontiers / PubMed.
7. Rouleau M., Schwab M., Klein K., Tremmel R., Haag M., Schaeffeler E., Guillemette C. The liver proteome of individuals with a natural UGT2B17 complete deficiency // Scientific Reports. – 2025. – Vol. 15. – Article 5458. DOI: 10.1038/s41598-025-89160-4. PMID: 39953065. Elektron manba: Nature / PubMed.